Literature DB >> 8630876

Factors related to enrollment in the breast cancer prevention trial at a comprehensive cancer center during the first year of recruitment.

A Yeomans-Kinney1, S W Vernon, R F Frankowski, D M Weber, J M Bitsura, V G Vogel.   

Abstract

BACKGROUND: Using an a priori theoretic model of behavior change, factors predicting enrollment in a randomized chemoprevention trial during the first year of recruitment were assessed prospectively.
METHODS: Eligible participants were asked to complete a 90-item semistructured questionnaire after attendance at an informational meeting. Components of the Health Belief Model (including perceived susceptibility, perceived severity, perceived benefits and barriers, cues to action, and health motivation), health status, preventive health behaviors, and social influence were assessed in relation to enrollment.
RESULTS: Overall, 331 women attended one of the meetings, and 73% completed a questionnaire; 45% enrolled on the trial and 55% did not. In bivariate analyses, all but one of the perceived barriers were associated negatively with enrollment; however, items assessing perceived susceptibility, perceived severity, and perceived benefits were not. Nonparticipants also were more likely to be over 49 years of age, to be currently or to have been on estrogen replacement therapy, and to have had hot flashes. In logistic regression analysis, not being able to take estrogen replacement therapy was the strongest predictor of nonparticipation (odds ratio [OR], 12.13, 95% confidence interval [CI], 3.63, 40.60). Other factors associated with nonparticipation were concern about side effects of tamoxifen (OR, 5.06; CI, 2.37, 10.80); the possibility of getting a placebo (OR, 7.75; CI, 1.51, 39.67); the costs associated with the trial (OR, 3.21; CI, 1.12, 9.24); and absence of concern that significant others would be reassured if the respondent was taking tamoxifen (OR, 2.58; CI, 1.04, 6.41).
CONCLUSIONS: These findings support the view that recruitment efforts for chemoprevention trials should address barriers specific to their circumstances. In addition, increasing the support available from personal social networks may enhance recruitment to chemoprevention trials for breast cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8630876     DOI: 10.1002/1097-0142(19950701)76:1<46::aid-cncr2820760107>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Correlates of adherence to a telephone-based multiple health behavior change cancer preventive intervention for teens: the Healthy for Life Program (HELP).

Authors:  Darren Mays; Beth N Peshkin; McKane E Sharff; Leslie R Walker; Anisha A Abraham; Kirsten B Hawkins; Kenneth P Tercyak
Journal:  Health Educ Behav       Date:  2011-05-31

2.  Choices for young women at intermediate risk of breast cancer.

Authors:  J Iqbal; S A Narod
Journal:  Curr Oncol       Date:  2012-06       Impact factor: 3.677

3.  Patterns and correlates of multiple risk factors for adult-onset cancer among adolescents(1).

Authors:  Darren Mays; Beth N Peshkin; Leslie R Walker; Anisha A Abraham; Kirsten B Hawkins; Kenneth P Tercyak
Journal:  J Child Health Care       Date:  2012-02-22       Impact factor: 1.979

4.  Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump.

Authors:  Rebecca Taylor; Kenneth Taguchi
Journal:  Ann Fam Med       Date:  2005 May-Jun       Impact factor: 5.166

5.  Problems of randomization to open or laparoscopic sigmoidectomy for diverticular disease.

Authors:  Wieland Raue; Corinna Langelotz; Vittorio Paolucci; Matthias Pross; Kaja Ludwig; Walter Asperger; Wolfgang Schwenk
Journal:  Int J Colorectal Dis       Date:  2010-10-17       Impact factor: 2.571

6.  Who wants to join preventive trials?--Experience from the Estonian Postmenopausal Hormone Therapy Trial [ISRCTN35338757].

Authors:  Sirpa-Liisa Hovi; Matti Hakama; Piret Veerus; Mati Rahu; Elina Hemminki
Journal:  BMC Med Res Methodol       Date:  2005-04-12       Impact factor: 4.615

7.  Methodological survey of designed uneven randomization trials (DU-RANDOM): a protocol.

Authors:  Darong Wu; Elie A Akl; Gordon H Guyatt; Philip J Devereaux; Romina Brignardello-Petersen; Barbara Prediger; Krupesh Patel; Namrata Patel; Taoying Lu; Yuan Zhang; Maicon Falavigna; Nancy Santesso; Reem A Mustafa; Qi Zhou; Matthias Briel; Holger J Schünemann
Journal:  Trials       Date:  2014-01-23       Impact factor: 2.279

Review 8.  Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review.

Authors:  B Meiser; W K T Wong; M Peate; C Julian-Reynier; J Kirk; G Mitchell
Journal:  Hered Cancer Clin Pract       Date:  2017-09-20       Impact factor: 2.857

9.  Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I).

Authors:  Samuel George Smith; Ivana Sestak; Anthony Howell; John Forbes; Jack Cuzick
Journal:  J Clin Oncol       Date:  2017-06-29       Impact factor: 44.544

Review 10.  Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis.

Authors:  S G Smith; I Sestak; A Forster; A Partridge; L Side; M S Wolf; R Horne; J Wardle; J Cuzick
Journal:  Ann Oncol       Date:  2015-12-08       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.